Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Eric
E
Raymond
Chantal
C
Dreyer
Sandrine
S
Faivre
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008495:Medical Oncology / Q000379:methods; D009362:Neoplasm Metastasis; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D000077204:Temozolomide; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D007211:Indoles; D011758:Pyrroles; D003606:Dacarbazine; D000077210:Sunitinib; D000077204:Temozolomide